Literature DB >> 12601091

Variability of total phenytoin serum concentrations within elderly nursing home residents.

A Birnbaum1, N A Hardie, I E Leppik, J M Conway, S E Bowers, T Lackner, N M Graves.   

Abstract

BACKGROUND: Approximately 6% of all elderly nursing home residents receive phenytoin. Phenytoin concentrations are often measured to guide therapy.
OBJECTIVE: To evaluate the intraresident variability among multiple measurements of total phenytoin serum concentrations in nursing home residents.
METHODS: This was an observational study of 56 elderly (>or=65 years) nursing home residents from 32 nursing homes who had at least 3 phenytoin concentrations measured while on the same dose of phenytoin for at least 4 weeks and who were not taking any interfering concomitant medications. These were a subset of 387 elderly nursing home residents from 112 nursing homes across the United States who had total phenytoin concentration measurements between June 1998 and December 2000.
RESULTS: The mean age was 80.1 years (range, 65 to 100 years) and 58.9% were women. The mean daily dose of phenytoin per resident was 4.9 +/- 1.5 mg/kg. Total phenytoin concentrations within an elderly nursing home resident varied as much as two- to threefold, even though there was no change in dose. The person with the smallest variability had a minimum concentration of 10.0 micro g/mL and a maximum of 10.4 micro g/mL. The person with the largest variability had a minimum concentration of 9.7 micro g/mL and a maximum of 28.8 micro g/mL.
CONCLUSIONS: There is considerable variability in the total phenytoin concentrations in the elderly nursing home resident and measurement of a single total phenytoin concentration should not be used to guide treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601091     DOI: 10.1212/01.wnl.0000052997.43492.e0

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

1.  Antiseizure, antidepressant, and antipsychotic medication prescribing in elderly nursing home residents.

Authors:  Sai Praneeth R Bathena; Ilo E Leppik; Andres M Kanner; Angela K Birnbaum
Journal:  Epilepsy Behav       Date:  2017-02-24       Impact factor: 2.937

2.  AED Treatment Through Different Ages: As Our Brains Change, Should Our Drug Choices Also?

Authors:  Jacqueline A French; Brigid A Staley
Journal:  Epilepsy Curr       Date:  2012-07       Impact factor: 7.500

3.  Type 1 Brugada pattern ECG due to supra-therapeutic phenytoin level.

Authors:  Thein Swe; Bikash Bhattarai; Alix Dufresne
Journal:  BMJ Case Rep       Date:  2016-06-28

Review 4.  Currently available antiepileptic drugs.

Authors:  Steven C Schachter
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

5.  Pathophysiological considerations of seizures, epilepsy, and status epilepticus in the elderly.

Authors:  Rebecca M Verellen; Jose E Cavazos
Journal:  Aging Dis       Date:  2011-08-30       Impact factor: 6.745

Review 6.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

Authors:  Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  Bioequivalence of antiepileptic drugs: how close is close enough?

Authors:  Barry E Gidal
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

Review 8.  Management of new-onset epilepsy in the elderly.

Authors:  Amir M Arain; Bassel W Abou-Khalil
Journal:  Nat Rev Neurol       Date:  2009-07       Impact factor: 42.937

9.  Treatment of epilepsy in the elderly.

Authors:  Ilo E Leppik
Journal:  Curr Treat Options Neurol       Date:  2008-07       Impact factor: 3.598

10.  Management of epilepsy in the elderly.

Authors:  Juan José Poza
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.